Physician profile
Dmitriy Shishkin
NPI 1891230371
$778.27
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $501 · 2022: $127 · 2023: $151.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $151.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $131.13 | 2021-2022 | |
| Kci USA, INC. | $126.50 | 2023 | Prevena, V.A.C. Veraflo, V.A.C. Veraflo Cleanse Choice |
| Glaxosmithkline, LLC. | $126.30 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.70 | 2021-2022 | |
| Novo Nordisk INC | $72.64 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $56.12 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.33 | 2021 | |
| Incyte Corporation | $24.50 | 2023 | Monjuvi, Pemazyre |
| Esperion Therapeutics, INC. | $20.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $19.88 | 2021 | |
| Biogen, INC. | $19.61 | 2021 | |
| Amarin Pharma, INC. | $17.96 | 2022 | |
| Abbott Laboratories | $17.75 | 2022 | |
| Lilly USA, LLC | $14.91 | 2021 | |
| Janssen Pharmaceuticals, INC | $12.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dmitriy Shishkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.